Bank OZK Acquires 78 Shares of Eli Lilly and Company (NYSE:LLY)

Bank OZK raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,622 shares of the company’s stock after purchasing an additional 78 shares during the period. Eli Lilly and Company comprises 4.6% of Bank OZK’s holdings, making the stock its 3rd largest position. Bank OZK’s holdings in Eli Lilly and Company were worth $10,522,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LLY. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth $32,000. Core Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares during the last quarter. Activest Wealth Management acquired a new stake in Eli Lilly and Company in the 1st quarter valued at about $39,000. Tidemark LLC purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $29,000. Finally, Unique Wealth Strategies LLC acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $45,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Johna Norton sold 7,056 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,097,883 shares of company stock worth $972,022,568. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Bank of America increased their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price target for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Barclays lifted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $19.82 during trading hours on Friday, reaching $960.02. 2,456,992 shares of the company’s stock were exchanged, compared to its average volume of 3,070,253. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $912.41 billion, a price-to-earnings ratio of 141.39, a P/E/G ratio of 1.81 and a beta of 0.41. The company has a 50-day moving average of $891.13 and a 200 day moving average of $819.99.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.54%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.